Celldex Therapeutics is rated a "Strong Buy" due to rapid enrollment in its phase 3 trials for barzolvolimab, targeting chronic spontaneous urticaria (CSU). The EMBARQ-CSU 1 and 2 trials completed enrollment six months ahead of schedule, with key data expected in September or October 2026 and a potential Biologics License Application (BLA) filing in 2027 if trial endpoints are met. The company is also advancing CDX-622, a bispecific inhibitor for asthma and inflammatory disorders, showing promising early results. A recent $323.9 million equity raise extends Celldex's cash runway through 2028, though additional funding or partnerships may be needed for long-term liquidity.
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
More than 1.16 trillion Shiba Inu (SHIB) tokens were transferred out of Coinbase-linked wallets in a rapid series of large moves, likely internal rebalancing rather than market selling or buying. Despite the massive transfer, SHIB's price stayed near...
International Petroleum (IPCFF) is benefiting from its Blackrod Project coming online during a period of rising commodity prices. The company has consistently repurchased shares and maintained a no-dilution policy, which has increased production per ...
Markets are currently dealing with a rare combination of shocks: conflict in the Middle East, renewed disruptions in shipping, and an expanding US tariff barrier. These factors push Brent crude oil prices near $100, impacting more than just energy st...
Crypto markets saw $26.3 million in liquidations over 24 hours, dominated by $18 million in short position liquidations as Bitcoin and Ethereum prices rose modestly. This indicates a short squeeze, where bearish traders are forced to close positions ...
